Welcome to GNQ Insilico
AI/Quantum Computing
Spearheaded by GNQ’s Chief Technology Officer, we are collaborating with industry leaders in leveraging quantum computing capabilities to optimize drug development.
Our Diverse Network of Partners.
THE PROBLEM
EXECUTIVE SUMMARY
“The ability to generate a very good quality technical sequence of the human genome exists. But there is a massive gap between having the data in front of us and knowing what it all means”.
Quote from December 2020 interview with Dr. Eric Green, head of the National Human Genome Research Institute (Leading US genomic research organization.)
The life sciences industry is under pressure due to increasing costs and time required to bring average drug to market. Traditional methods of conducting clinical trials may not be sustainable as high rates of failure exceed revenues from new drugs.
OUR SOLUTION
Collaboration with Fortune 100 company for groundbreaking development of our cutting-edge genomics driven AI platform, dedicated to transforming the drug development process by enabling pharmaceutical companies to bring drugs to the market faster.
OUR VISION
To improve human health by accelerating the world’s transition to precision medicine
OUR MISSION
To improve the success of drug discovery and development through Genomics, AI and Quantum Computing
Our Pipeline
Current Focus Areas
Our Products
Drug Assessment Platform (DAP)
The GNQ Drug Assessment Platform (DAP) represents a breakthrough in computational drug development and due diligence, providing investors and pharmaceutical companies with an unprecedented depth of molecular and clinical insights.
Drug Assessment Platform (DAP)
The GNQ Drug Assessment Platform (DAP) represents a breakthrough in computational
Bio Digital Twins Platform
Our Bio Digital Twins Platform represents a revolutionary approach to personalized healthcare
Future Directions: 3D Bioprinting
Our roadmap includes advanced 3D bioprinting capabilities to
Our Insight
Long-Term Vision
GNQ has a clear long-term vision for its role in the drug discovery and healthcare ecosystem. This includes planning for scalability, sustainability, and adaptation to evolving technologies and market dynamics.
CONTACT US
GNQ's approach takes a comprehensive approach essential for gaining insights into complex diseases including factors influencing cellular behaviours such as genetic pathways, environmental factors, lifestyle choices, diet, exercise, and more.
Membership
Your Gateway to Premium Crypto Services
Commodo nec mi id ullamcorper vitae augue neque dis. Nunc lacinia viverra orci diam. Nibh est vitae suspendisse parturient sed lorem eu.
Entry Level
Basic Membership
In lobortis justo tortor viverra. Quis uismod purus cursus ultricies faucibus fringilla.
- Access to beginner crypto courses
- Monthly market insights newsletter
- Limited access to trading tools
- Community forum participation
- Discount on select partner services
Intermediate Level
Pro Membership
In lobortis justo tortor viverra. Quis uismod purus cursus ultricies faucibus fringilla.
- Full access to advanced crypto courses
- Weekly market analysis reports
- Set of trading tools and indicators
- Priority support from our team
- Exclusive webinars and events
Premium Level
VIP Membership
In lobortis justo tortor viverra. Quis uismod purus cursus ultricies faucibus fringilla.
- Personalized one-on-one consultations
- Daily market alerts and insights
- Access to exclusive research and reports
- Customized portfolio management
- Invitations to VIP events and networking
LEADERSHIP
Combine proprietary genomics insights, AI along with quantum computing in the hybrid cloud for number of applications
Rehan Huda
Founder, Chairperson, Board of Directors and Chief Executive Officer
Sudhir Saxena
Chief Technology Officer
Asif Mustafa
Chief Financial Officer
Dr. Jerome Schentag
Chief Operating Officer
Download App
Get the Nextronium App: Your Crypto Companion
Commodo nec mi id ullamcorper vitae augue neque dis. Nunc lacinia viverra orci diam. Nibh est vitae suspendisse parturient sed lorem eu.
